Lsv Asset Management Catalyst Pharmaceuticals, Inc. Transaction History

Lsv Asset Management

$41.9 Billion
Q2 2025

A detailed history of Lsv Asset Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 577,700 shares of CPRX stock, worth $11.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

577,700

Previous 703,802 17.92%

Holding current value

$11.9 Million

Previous $17.1 Million 26.55%

% of portfolio

0.03%

Previous 0.04%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$21.4 - $26.31 $2.7 Million - $3.32 Million	-126,102 Reduced 17.92%	577,700 $12.5 Million
Q1 2025 May 08, 2025	SELL	$19.53 - $25.74 $1.43 Million - $1.89 Million	-73,322 Reduced 9.44%	703,802 $17.1 Million
Q4 2024 Feb 13, 2025	SELL	$19.73 - $23.93 $3.44 Million - $4.17 Million	-174,200 Reduced 18.31%	777,124 $16.2 Million
Q3 2024 Nov 12, 2024	BUY	$15.19 - $21.35 $1.18 Million - $1.65 Million	77,424 Added 8.86%	951,324 $18.9 Million
Q2 2024 Aug 06, 2024	SELL	$14.68 - $16.92 $324,428 - $373,932	-22,100 Reduced 2.47%	873,900 $13.5 Million
Q1 2024 May 06, 2024	SELL	$13.18 - $17.11 $4.41 Million - $5.73 Million	-334,700 Reduced 27.2%	896,000 $14.3 Million
Q4 2023 Feb 06, 2024	SELL	$11.78 - $17.29 $118,612 - $174,093	-10,069 Reduced 0.81%	1,230,700 $20.7 Million
Q3 2023 Nov 03, 2023	BUY	$11.69 - $15.02 $2.96 Million - $3.8 Million	253,100 Added 25.63%	1,240,769 $14.5 Million
Q2 2023 Aug 02, 2023	BUY	$11.5 - $18.08 $343,493 - $540,031	29,869 Added 3.12%	987,669 $13.3 Million
Q1 2023 May 02, 2023	SELL	$14.34 - $21.05 $855,682 - $1.26 Million	-59,671 Reduced 5.86%	957,800 $15.9 Million
Q4 2022 Feb 08, 2023	SELL	$12.25 - $19.5 $29.1 Million - $46.4 Million	-2,377,018 Reduced 70.03%	1,017,471 $18.9 Million
Q3 2022 Nov 07, 2022	SELL	$7.06 - $15.52 $4.48 Million - $9.86 Million	-635,188 Reduced 15.76%	3,394,489 $43.6 Million
Q2 2022 Aug 10, 2022	BUY	$6.23 - $8.57 $2.03 Million - $2.8 Million	326,405 Added 8.81%	4,029,677 $28.2 Million
Q1 2022 May 12, 2022	SELL	$5.31 - $8.31 $1.85 Million - $2.9 Million	-348,797 Reduced 8.61%	3,703,272 $30.7 Million
Q4 2021 Jan 28, 2022	SELL	$5.21 - $7.45 $6.29 Million - $9 Million	-1,207,636 Reduced 22.96%	4,052,069 $27.4 Million
Q3 2021 Nov 04, 2021	BUY	$4.85 - $6.04 $4.94 Million - $6.16 Million	1,019,389 Added 24.04%	5,259,705 $27.9 Million
Q2 2021 Aug 04, 2021	BUY	$4.29 - $6.05 $12.1 Million - $17.1 Million	2,829,579 Added 200.57%	4,240,316 $24.4 Million
Q1 2021 Apr 30, 2021	SELL	$3.45 - $4.69 $284,280 - $386,456	-82,400 Reduced 5.52%	1,410,737 $6.5 Million
Q4 2020 Feb 08, 2021	SELL	$2.97 - $3.83 $300,267 - $387,213	-101,100 Reduced 6.34%	1,493,137 $4.99 Million
Q3 2020 Oct 23, 2020	BUY	$2.97 - $5.08 $4.23 Million - $7.24 Million	1,424,544 Added 839.48%	1,594,237 $4.73 Million
Q2 2020 Aug 05, 2020	BUY	$3.48 - $5.05 $590,531 - $856,949	169,693 New	169,693 $783,000

Others Institutions Holding CPRX

# of Institutions

386

Shares Held

103M

Call Options Held

Put Options Held

277K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.11B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.

Account

Lsv Asset Management Catalyst Pharmaceuticals, Inc. Transaction History